Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SA Transcripts 162.14K Followers Follow Beam Therapeutics Inc. ( BEAM ) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 1:00 PM EDT Company Participants Sravan Emany - Chief Financial Officer John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Citigroup Inc., Research Division I'm Sam Semenkow, one of the senior biotech analysts here at Citi. And it is my pleasure to be hosting Beam at Citi's 2026 Biopharma Back To School Summit. I'm joined by John Evans, CEO; and Sravan Emany, CFO. John and Sravan, welcome, and thank you both for being here. Sravan Emany Chief Financial Officer Thanks for having us. Question-and-Answer Session Samantha Semenkow Citigroup Inc., Research Division So why don't we just start by level setting. You've made a lot of progress across the pipeline this year. Just tell us where the company stands today and what we can expect through the end of the year and beyond. John Evans CEO & Director Yes. Great. So Beam has made a lot of progress. We're moving very quickly now across a broad range of programs, all building off of this very dynamic platform that we've created using base editing, of course, next-generation CRISPR 2.0 technology for more precise gene editing, but then building that into a delivery and manufacturing machinery that is now quite mature. So doing both ex vivo cell therapy, but also now in vivo lipid nano particle part programs and manufacturing all of that internally. So it's a very significant capability we've built. The programs are now moving very quickly. So risto-cel, our sickle program, is really awaiting its final data cut from a now fully enrolled and dosed BEACON trial. That will become a BLA filing right around the end of the year, which will be our first BLA. So that will be an update we're